China: What Does The Third Amendment To China´s Patent Law Mean To You?

Since its enactment in 1984, China's Patent Law ("the Patent Law") has been amended three times: first in 1992, then in 2000, and most recently in 2008. The first amendment added pharmaceutical compositions to the list of patentable subject matter and inaugurated China's membership in the Patent Cooperation Treaty. The second amendment was intended to bring the Patent Law into compliance with the Trade-Related Aspects of Intellectual Property Rights Agreement ("TRIPS").

The widely expected and long-awaited third amendment to the Patent Law was passed by the National People's Congress on December 27, 2008, and will go into effect on October 1, 2009. This Commentary discusses several significant changes to the Patent Law brought by the third amendment ("Amendment") and their potential impact on patent protection in China.

Heightened Patentability Standard—Adoption of Absolute Novelty

Article 22.2 of the current Patent Law has a blended novelty standard for patentability—in assessing novelty of an invention, one considers publication anywhere in the world but not public use or knowledge outside of China. This blended novelty standard occasionally allows "patent hijacking," i.e., the patenting in China of another's invention witnessed at a public event (such as a trade show) outside of China. The Amendment replaces this blended novelty standard with an absolute one and defines "prior art" as publicly known art anywhere in the world before the filing date.

This new novelty standard applies across the board to all three categories of patents: invention patents, utility model patents, and design patents. Therefore, this new patentability standard will have a significant impact on the way in which patent validity is challenged in China. For example, under the current law, public use outside China does not destroy novelty and is, therefore, irrelevant in invalidation proceedings. Under the new law, however, it will be highly relevant, as will evidence of overseas public sale, public dissemination, and public knowledge.

Moreover, the adoption of an absolute novelty standard will have the effect of reducing patent hijacking. The Amendment does not state whether and to what extent this absolute novelty requirement would be made retroactive to previously granted patents or pending applications. If so, the Amendment would make prior art significantly more available for challenging the validity of existing Chinese patents.

Clarification of Double Patenting

As mentioned, China has three types of patents: invention patents, utility model patents, and design patents. A Chinese invention patent is similar to a United States utility patent and protects a new technical solution relating to a product, a process, or an improvement thereof. An invention patent has a 20-year term. A Chinese utility model patent, on the other hand, covers a new technical solution relating to a product's shape, structure, or a combination thereof. A utility model patent has a 10-year term. Utility model patents are not substantively examined and are granted after formality examination, which generally takes about one to one-and-a-half years or less. In contrast, invention patents are substantively examined and can take three to five years to grant. Therefore, it is advantageous to have early issuance of a utility model patent to sue for infringement or to serve as a deterrent, in addition to or in substitution for an invention patent.

It has been a widespread practice of patent applicants to obtain invention patents and utility model patents on the same inventions, although such a practice has been frowned upon by courts. Therefore, some double patenting has occurred in China. This practice continued until the State Intellectual Property Office ("SIPO") amended its Patent Examination Guidelines to limit its occurrence in July 2007.

The Amendment substantially adopts the 2007 SIPO approach and stipulates that the same invention can only be granted one patent at any given time. While the same applicant can file an application for both invention patent and utility model patent directed to an identical invention on the same day, the invention patent can be granted only when the applicant declares his intention to abandon the previously granted utility model patent if such utility model patent has not lapsed.

However, ambiguities still exist. For example, it is not clear whether the prohibition against double patenting applies only to same-invention double patenting (i.e., applications with identical claims), or whether it also applies to obviousness-type double patenting (i.e., applications with different yet patentably indistinguishable claims). Furthermore, it is not clear whether a genus claim and species claim will be considered as double patenting.

Improvements on Design Patents

The Amendment in amended Article 23 introduces an absolute novelty standard in assessing the novelty of a design. Moreover, a patentable design must possess a prominent difference from prior art designs and combinations thereof. In other words, design patents will be subject to the same novelty standard as invention patents. It also appears that a new design must not be obvious over prior art. This is a welcome change because SIPO currently does not impose, in practice, an obviousness standard in determining the patentability of design patents. This lack of an obviousness standard in practice, coupled with a narrow novelty standard, has resulted in many "junk" design patents being issued in China.

In addition to raising the patentability standards for designs, the Amendment no longer allows the registration of trademarks and labels as design patents. The combination of these changes in effect plugs many of the loopholes widely used in China by some applicants who register other parties' marks as design patents and use the design patents as shields against enforcement by the trademark owners. After October 1, 2009, it is expected that fewer junk design patents will be applied for and granted.

Another change brought by the Amendment is that an offer for sale is an infringing act under the amended Patent Law, enabling patentees to pursue claims of infringement at trade fairs or wholesale markets.

Tough Disclosure Rules for Inventions Relying on "Genetic Resources"

China is rich in genetic resources, and the Chinese government supports and encourages research to lawfully develop intellectual property derived from these assets. For inventions that rely on genetic resources, the Amendment for the first time imposes a requirement that the patent applicant disclose in the application the direct source of the genetic resources. In addition, the applicant must disclose the original source of the genetic resources or provide a reason explaining why he is unable to do so, if the original source cannot be identified. The prospective patentee must also prove that the access to such genetic resource was lawfully obtained.

The Amendment also stipulates that no patent shall be granted to inventions that rely on genetic resources if the acquisition or use of the underlying genetic resources violated Chinese law or regulation. These changes reflect discussions held at the Convention on Biological Diversity ("CBD") and were adopted after consultation by the Chinese government with other biologically diverse countries, as well as discussions with the United States and other countries that were concerned about introduction of CBD-related concepts into patent examination.

The impact of these provisions will largely depend on how "reliance" on "genetic resources" is defined and what constitutes illegal acquisition and use. The Amendment does not provide a definition of "genetic resources," nor does it limit "genetic resources" to those in China only. According to CBD, "genetic resources" means genetic material of actual or potential value, and "genetic material" refers to any material of plant, animal, microbial, or other origin containing functional units of heredity. China's interest in protecting genetic resources needs to be balanced with its interest in providing certainty in patent grants, encouraging development of a biotech R&D sector, and pursuing cooperative arrangements with other countries that reflect the risks involved in biotechnology research. Until the scope of these provisions is clarified in the Implementing Regulations and examination guidelines (the revision of which is under way by SIPO at the time of this writing), prudent companies will want to make sure that the genetic resource on which the completion of the invention relies is subject to proper access and benefit-sharing mechanisms.

Biotechnology companies need to pay close attention to this disclosure requirement because failure to comply could result in either the denial or invalidation of a Chinese patent. It should be noted that there is no equivalent requirement in the patent laws of Europe, Japan, or the United States.

Heavy Penalty for Foreign Filing Without a License

As international companies set up research and development centers in China, they need to consider where first to file patent applications for inventions completed in China. Today, Article 20.1 of the Patent Law requires that a Chinese patent applicant for an invention completed in China must first file a patent application in China before any foreign filing. However, the current law is silent about what a foreign applicant is required to do in the same situation. Consequently, some foreign-owned research labs in China circumvent the first-to-file requirement of the current Patent Law by assigning patent applications for inventions completed in China to one of its foreign entities and then having the patent applications filed outside of China first in the name of that foreign entity.

The Amendment provides that patent applications for inventions completed in China may be filed directly outside of China (i.e., in the United States) without the need of first filing in China (as prescribed under the current law). However, prior to filing outside of China, applicants should submit the invention to SIPO for review for the purposes of protecting State secrets. Violation of the review requirement will result in loss of patent rights in China. SIPO is drafting Implementing Regulations for the new Patent Law, and it expects that the procedure for the State secret review would be set out in the Implementing Regulations; however, it is expected based on current discussions that the submission for the review would not involve disclosure of the invention to the degree required for patent filing.

Finally, although there is no statutory definition for inventions "completed in China," the understanding is that inventions jointly made in China by Chinese inventors and non-Chinese inventors are subject to this requirement.

Clarification of Patent Joint-Ownership Rights

As multinational companies enter into research collaborations with Chinese universities and companies, they need to understand how Chinese law governs the commercialization of jointly developed and owned patent rights. In that regard, the Amendment includes provisions that govern unilateral exploitation of the patent rights without the consent of joint owners.

Specifically, the Amendment states in new Article 15 that unless otherwise agreed upon, a joint owner can individually exploit or allow another to exploit the patent by means of a general license, but must share the royalties obtained thereof with other joint owners. The Amendment does not stipulate how the royalties are to be distributed. Consent by all joint-owners is required for other means of exploiting the jointly owned patent. Under such rules, multinational companies should draft collaborative research agreements in ways to ensure that commercial use of the patent rights arising from the joint research efforts will not be blocked by the default veto power of the joint owner(s).

Road Map for Compulsory Licenses

No compulsory license has ever been granted in China by SIPO, even though Chapter VI of the current Patent Law contains compulsory license provisions and China implemented the Doha Declaration through a National People's Congress decision on accession as well as through SIPO's Measures for the Compulsory Licensing of Patents Relating to Public Health Issues ("Pharmaceutical Compulsory Licensing Measures"). The Amendment provides a more definitive statutory basis to compel compulsory licenses, implements the Doha Declaration into the Patent Law, and contains new rules that restrict the general scope of compulsory licensing while making it more feasible and likely for compulsory licenses to be granted in the area of pharmaceuticals (new Article 50) and semiconductor technology (new Article 52).

China has long provided a working requirement in its Patent Law. Under the current Patent Law, compulsory licensing may be granted where an entity is unable to obtain a license on reasonable terms and conditions within a reasonable period of time. The Amendment, however, restricts the scope for compulsory licensing to the standard 1) that the patentee has not exploited or has not sufficiently exploited the patent rights without any reasonable grounds within three years since the date that the patent rights were granted and four years since the date of filing, or 2) if the patentee exploits the patent in a manner determined to be an "act of antitrust."

The Amendment has adopted a broader standard than that of the Pharmaceutical Compulsory Licensing Measures for issuing compulsory licensing of pharmaceuticals for any public health purposes. That is, the compulsory licensing provided under the Amendment is no longer limited to just "for the treatment of contagious diseases" as under the Pharmaceutical Compulsory Licensing Measures. This theoretically opens up a broad range of pharmaceutical therapies to compulsory licensing.

In the event of a public health crisis, such as SARS or bird flu, the Chinese government is likely to grant a compulsory license to manufacture and export the required patented drugs. For other nonpublic health matters (e.g., green technology), however, it remains to be seen if the SIPO is equally willing to grant a compulsory license. Recently, Chinese courts reportedly have denied a request for injunction in a patent infringement case after the patentee prevailed. This could signal the beginning of court-mandated compulsory licenses in China.

In addition to health-related compulsory licensing, the Amendment also provides that the Chinese government may grant a compulsory license on a patent involving semiconductor technology if the license for exploitation is limited to use for the purposes of public interest.

The amended Patent Law is now inextricably intertwined with the Anti-Monopoly Law in China. For example, Article 55 of China's Anti-Monopoly Law provides that "[t]his Law is not applicable to conduct by business operators to exercise their legitimate intellectual property rights in accordance with intellectual property laws and relevant administrative regulations; however, this Law is applicable to the conduct of business operators to eliminate or restrict market competition by abusing intellectual property rights." This very general language appears to present a concept similar to patent misuse under United States law, where, for example, a patent holder would not be permitted to seek to leverage its lawful monopoly IP rights to extend them beyond the proper scope of the patent. Article 48 of the amended Patent Law stipulates that compulsory licensing may be granted to remove or reduce the negative effects of competition due to monopoly acts caused by the patentee exploiting the patent. In other words, the issuance of a compulsory license is now a remedy for patent misuse. However, what constitutes patent misuse in China is yet to be defined. China may look to the United States and Europe for guidance when dealing with patent misuse.

Codification of Prior Art Defense

China has a split patent litigation system, with infringement determined by the courts and invalidity challenges heard initially by SIPO's Patent Reexamination Board. Therefore, patent infringement and invalidation proceedings often run parallel to each other. If the infringement proceeding progresses more quickly than the parallel invalidation proceeding, this could be rather disadvantageous to defendants, especially when the only viable defense is practicing what is in the prior art. While Chinese courts can stay the infringement proceedings pending the results of invalidation proceedings, they are not required to do so. Stays in design patent suits or utility model patent suits are granted more often than not, but most invention patent infringement suits are not stayed.

The current Patent Law does not explicitly identify practicing prior art as a defense to a claim of patent infringement. In practice, however, Chinese courts have allowed the prior art defense. The Amendment now codifies such judicial practice.

While it is not clear from the Amendment whether an accused infringer must practice exactly what is in the prior art, Chinese courts are likely to follow the approach taken by the Chinese Supreme People's Court in a 2001 advisory opinion concerning such defense.1 According to the Chinese Supreme People's Court, the prior art defense can be established by showing that the accused product or process is identical to or obvious in view of the prior art.

Regulatory Exemption for Infringement

In many countries, their patent law provides a research exemption or safe harbor exemption as an exception to the exclusive rights conferred by patents, which is especially relevant to drugs. According to this exemption, despite the patent rights, performing research and tests for regulatory approval, for instance, does not constitute infringement before the end of the patent term. In the United States, this exemption, known as the Hatch-Waxman exemption, is codified in 35 U.S.C. § 271(e)(1).

The Patent Law does not expressly exempt activities related to regulatory review from patent infringement. Such an exemption currently exists as a judicial interpretation of the broad experimental use exception provided in the Patent Law. A Beijing Intermediate People's Court also recognized such exemption in its noninfringement findings. The Amendment codifies the judicial interpretation and practice by stating that it is not an act of infringement if a patented drug or medical apparatus is manufactured, used, or imported solely for the purposes of obtaining and providing information for administrative approval.

While the Amendment formalizes the exemption for activities related to regulatory review (this is a so-called "naked" Bolar exemption), it does not provide any provision for patent linkage with marketing approval. In addition, China does not afford patent term extension or patent term restoration, to compensate for regulatory delays in obtaining State Food and Drug Administration approval of drugs. Although some form of patent linkage has already been prescribed in the Pharmaceutical Registration Regulation, and the Chinese FDA has a set of procedures for implementing such patent linkage, it is essentially a toothless linkage scheme. This is because under this scheme, it is not an act of infringement to seek marketing approval. As such, it is of limited value.

International Patent Exhaustion

The current Patent Law in Article 63 provides for domestic patent exhaustion, which applies to a product sold by the patentee in China. However, the language of Article 63 is not clear with respect to the importation into China of a product sold by the patentee outside China. The Amendment clearly provides for both domestic and international exhaustion of patent rights. Under the Amendment, it is not patent infringement when "anyone uses, offers to sell, sells or imports a patented product or a product directly obtained from a patented process, which has been sold by the patentee or by an entity or individual authorized by the patentee." The addition of "imports" makes it clear that the parallel importation of patented products is not considered patent infringement in China.

The language of the amended statute does not make a distinction between restricted sales and unrestricted sales. Therefore, it is not clear whether international patent exhaustion can be prevented by contractual restrictions on the products sold. Moreover, international exhaustion, contractual restrictions, and antitrust issues interact in complex ways, and companies need to carefully structure their relationships in different jurisdictions to best achieve their business and commercial goals.

Preliminary Injunction Procedures

Article 61 of the current Patent Law authorizes courts to issue injunctions before filing an infringement suit, which may be translated as China's efforts to implement its obligations to provide preliminary injunctive relief in patent infringement cases. In China, this is referred to as "pre-suit injunction." The Judicial Interpretations on Application of Laws in Trials of Patent Related Lawsuits issued in 2001 by the Chinese Supreme People's Court provides some procedural guidelines. Upon receiving a request for a preliminary injunction, a court must make a ruling within 48 hours if it finds that all procedural requirements have been properly met. The 48-hour time limit can be extended in special circumstances. Once issued, the injunction is immediately enforceable. The patentee, if it has not done so already, must then initiate an infringement action in the courts within 15 days of issuance of the injunction, or the injunction will be lifted automatically. Either party may request the issuing court to reconsider its decision, which is an administrative procedure within the court. However, the injunction will remain enforceable during reconsideration and any subsequent proceedings until final judgment.

The Amendment incorporates the above procedures and further clarifies that the posting of a bond for a preliminary injunction motion is required. If no bond is posted, the motion will be denied. Moreover, the petitioner (i.e., the movant) is responsible for any loss sustained by the respondent if the petitioner makes a mistake in the motion for preliminary injunction.

Notwithstanding the codification of preliminary injunction, obtaining a preliminary injunction in most patent infringement cases in China has always been and is becoming increasingly more difficult. Both infringement and irreparable harm must be clearly proven—a burden that is not easy to meet in China given the stringent evidentiary requirements and the lack of discovery procedures. Moreover, the Supreme People's Court a few years ago tempered any early enthusiasm for the issuance of such injunctions by issuing an instruction to the lower courts urging caution in issuing preliminary injunctions and noting that preliminary injunctions should not be issued in cases involving nonliteral infringement or complicated technologies. Statistically, most plaintiffs in patent infringement cases do not seek a preliminary injunction for these reasons. For those who do request a preliminary injunction, the success rate is relatively high (i.e., greater than 50 percent). It is yet to be seen if the statistics will change after the effective date of the Amendment.

Codification of Evidence Preservation

Article 74 of the Chinese Civil Procedure Law provides for "evidence preservation." Where there is a likelihood that evidence may be destroyed or lost or difficult to obtain later, a party may seek an ex parte court order to seize such evidence before initiating a suit. The court may demand that the requesting party post a bond. An evidence preservation order is typically enforced by the judges themselves. Such orders can be very effective, as the respondent generally will not be notified in advance and may be required to comply by providing the relevant documentation and evidence on the spot. In the execution of the order, the court may question the respondent, order production of documents, take samples of the infringing product, as well as conduct an inspection of the premises. Any evidence obtained from evidence preservation efforts is admissible in the subsequent court proceeding. Therefore, evidence preservation has become a powerful tool in patent litigation in Chinese courts. To prevent its abuse, however, most courts will require that the movant present some preliminary evidence showing ongoing or imminent infringement before issuing such an order.

The Amendment incorporates the above procedures into the amended Patent Law. Similar to the preliminary injunction procedures, a court should normally decide a motion for evidence preservation within 48 hours of receiving the motion. Once granted, the evidence preservation order must be executed immediately. The movant, on the other hand, must file a patent infringement suit within 15 days of the grant of the order. Otherwise, the court may nullify this procedural remedy, presumably by returning the obtained evidence to its owner.

Increased Statutory Damages

Under the current Patent Law, infringement damages are assessed on the basis of the following factors, in descending order of importance: (1) the actual loss suffered by the patentee; (2) the profits made by the infringer due to infringement; and (3) a multiple of the reasonable royalty found by the court. Where there is insufficient evidence of the patentee's loss, infringer's profits, or reasonable royalty, Chinese courts often award total damages of up to RMB 500,000 (about US$72,500). Such damages award is prescribed in a Supreme People's Court judicial interpretation (which carries legal force in China). The Amendment codifies the award of statutory damages and also increases the upper limit to RMB 1,000,000 (about $145,000). Moreover, the Amendment provides for the award of reasonable expenses incurred by the patentee to stop infringement that has already been in existence in regulations. However, in the past, Chinese courts only allowed very low recovery of expenses, and the situation is not likely to change.

Conclusion and Next Steps

As indicated, the Amendment will come into effect on October 1, 2009. SIPO is currently working with the State Council Legislative Affairs Office to draft Implementing Regulations to the amended Patent Law, which are expected to also come into effect on October 1, 2009. Other rules, such as examination guidelines and revised rules regarding compulsory licensing, are being drafted to further implement the changes mandated by the Patent Law. At the same time, it can be expected that corresponding changes will be made in the existing judicial practice regarding patents, including changes to judicial interpretations and other guidance regarding patent infringement lawsuits. Importantly, the amended Patent Law left out two important issues. First, the doctrine of equivalents, which was in an earlier draft of the Patent Law, was not ultimately adopted into law. Chinese drafters and jurists noted that the doctrine of equivalents is largely a judge-made doctrine, and they therefore deemed it unnecessary to enact it into statutory law. Second, China had also contemplated legislating two other judicial doctrines: estoppel and laches, into the Patent Law. As China's statute of limitations for patent litigation is two years, the further addition of concepts of laches or estoppel could have further eroded a patentee's ability to seek full compensation for infringement. Moreover, it appears that consideration of such doctrines may need to await further revisions of other laws, as they could potentially affect other forms of civil litigation by their introduction into Chinese litigation practice.

The Third Amendment to the Patent Law contains sea changes that will significantly affect how Chinese and multinational companies will compete on the basis of patents in this emerging market. China is expected to generate more patentable inventions, and more patent applications will be filed and granted in China on behalf of applicants from overseas. The new law may change the way the patent game is played in China. First, patent invalidation will become more complicated because foreign evidence of prior public use, dissemination, and knowledge will constitute prior art under the new law. Second, patent litigation will also become more complex since the new law will allow the prior art defense and international patent exhaustion. Therefore, more skilled patent litigators are needed to navigate through this uncharted water. Third, multinational companies will have to develop a proactive yet practical strategy for dealing with the possibility of compulsory licensing of patents in China. Finally, for those companies with R&D centers in China, there must be a patenting strategy that works for China, as well as the rest of the world.

As noted, the language of the Amendment is far from clear, so ambiguities still abound. Many of the ambiguities remain to be clarified in new regulations, rules, or judicial interpretations. Stay tuned for updates in the near future.


1. Chinese Supreme People's Court Reply Letter No. 32[2002] of February 2, 2001

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
13 Dec 2017, Seminar, Cleveland, United States

Jones Day partners Harold Gordon and Tony Dias, and Associate Courtney Snyder will explore the significant role New York's Attorney General and its Department of Financial Services (DFS) play in the financial services industry and why these two state-level agencies will continue to exert significant power over the financial services industry, especially with federal oversight potentially shrinking.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions